Key Highlights
- StoneX Group (NASDAQ:SNEX) led the four with a 19.76% intraday decline to USD 43.18 on November 19, 2026, as quarterly Net Income of USD 84.2 million came in 2% lower.
- SELLAS Life Sciences (NASDAQ:SLS) slid 13.98% to USD 15.44 intraday, one day after a USD 150.0 million public offering was proposed, plus an underwriter option worth up to USD 22.5 million over 30 days.
- Akanda (NASDAQ:AKAN) eased 13.9% to USD 3.47 intraday after a surge that published coverage put at 102.47% in a single session, and no company announcement for the move was found.
- ClearOne (NASDAQ:CLRO) gave up 11.59% to USD 6.10 intraday, with its share count now 3,675,411 after 999,999 new shares were issued at USD 4.00.
StoneX Group (NASDAQ:SNEX): A Record Year Cannot Hide a Softer Quarter
StoneX Group (NASDAQ:SNEX) shed the most value of the four on Thursday, November 19, 2026, falling 19.76% to USD 43.18 in intraday market data. A prior close near USD 53.82 follows from those two numbers (calculated). Results for fiscal 2026, dated November 18, 2026, showed a fourth quarter softer than the twelve months around it. Earnings Per Share of USD 0.66 were 6% lower on a split-adjusted basis, net income of USD 84.2 million was 2% lower, and quarterly Return on Equity sank to 11.6% from 15.2%. The quarter also absorbed an unrealized mark-to-market hit of USD 17.9 million on Treasury and agency holdings. By segment, Commercial income climbed 66% to USD 188.1 million, whereas Institutional income shrank 25% and Self-Directed/Retail income lost 56%. Across the whole year, net income still rose 72% to USD 525.4 million. A consensus comparison was not verified, which leaves the scale of any shortfall unconfirmed. The main risks are quieter markets, tighter trading spreads and a return on equity running well under the 19.5% earned for the year.
SELLAS Life Sciences (NASDAQ:SLS): A Big Equity Raise Arrives After the Phase 3 Rally
SELLAS Life Sciences (NASDAQ:SLS) dropped 13.98% to USD 15.44 intraday, which points to a prior close near USD 17.95 (calculated). Financing is the development that stands out. Earlier in the week, on November 17, 2026, the company said its Phase 3 REGAL study of galinpepimut-S in acute myeloid leukemia reached its overall survival goal, and it then proposed an underwritten common stock offering of USD 150.0 million. Management, not existing holders, is the only seller, with J.P. Morgan and TD Cowen as joint book-running managers. New shares dilute existing ownership, and underwriters commonly set deal prices beneath the last trade, so the decline fits that pattern, although nothing beyond the offering was found. No per-share price appeared in the release, and final pricing was not confirmed. The Balance Sheet held USD 134.7 million of cash on September 30, 2026, and the third-quarter net loss was USD 10.1 million. Risks include an open-label design, a p-value of 0.035, only 126 patients and the chance that regulators request more evidence before a planned application in the first half of 2027.
Akanda (NASDAQ:AKAN): A Triple-Digit Run Gives Back Ground
Akanda (NASDAQ:AKAN) fell 13.9% to USD 3.47 intraday, implying a prior close near USD 4.03 (calculated). Nothing from the company explains the move. Single-source published coverage reported a 102.47% gain in one recent session, plus a 41.9% advance on November 16, 2026, measured from the preceding Friday close of USD 1.36, all on very heavy volume. Profit-taking after such a climb is a plausible reading, but it remains an inference. The Business behind the ticker is small: Akanda dropped cannabis cultivation plans on September 24, 2026 and now focuses on First Towers, a Mexican operator of dark fiber and telecom towers. Half-year results to June 30, 2026 showed Revenue of USD 404,000, a net loss of USD 6.25 million and a Working Capital Deficit of USD 9.7 million, and management raised substantial doubt about continuing as a going concern. An amended registration dated November 6, 2026 listed roughly 2.39 million shares outstanding alongside a proposed USD 10 million convertible preferred offering. With so few shares, spreads can be wide and quoted moves can reverse.
ClearOne (NASDAQ:CLRO): Fresh Shares Sold Well Below the Market Quote
ClearOne (NASDAQ:CLRO) lost 11.59% to USD 6.10 intraday, from a prior close near USD 6.90 (calculated). A separate announcement for the move was not found. Filings do show a Placement completed on November 17, 2026, in which 999,999 shares were issued at USD 4.00 for total consideration of USD 3,999,998. About USD 2.756 million arrived as gross cash, and Debt owed to First Finance of USD 1,244,458 was swapped for 311,114 shares. The count of shares outstanding is now 3,675,411, and the new issue makes up about 27% of that (calculated). The deal is tied to a Nasdaq listing dispute, since staff moved on October 8, 2026 to delist the stock for missing the USD 2.5 million equity minimum. A hearing was set for November 17, 2026. The company put preliminary, unaudited pro forma equity at USD 3.282 million, a level Nasdaq has not yet accepted as sufficient. Published coverage, reported here as unconfirmed, also described zero continuing revenue and a pending Merger with Cortigent and Vivani Medical. Thin trading means quoted moves can reverse, and the stock trades well above the USD 4.00 issue price.
Where Things Stand
The four fell for different reasons, so no single force explains the slide. StoneX Group (NASDAQ:SNEX) dropped furthest because a soft quarter followed an exceptional year. New share issuance sits behind the SELLAS and ClearOne declines, a proposed USD 150.0 million raise in one case and a completed sale at USD 4.00 in the other. Akanda fell with no catalyst found, after a rally that looks volume-driven. Only StoneX is a large operating business with verified quarterly numbers, while the other three combine thin trading with financing or listing risk. Next markers are the StoneX Form 10-K, SELLAS offering terms, any Akanda preferred pricing and the Nasdaq hearing outcome for ClearOne. None of this guarantees any direction for these shares, and each of the four moves is an intraday figure that can change before the session ends.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...